ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
1 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
168
|
47K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
2 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
0 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
3
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL to Present at Bioshares Biotech Summit - Presentation
|
|
Cuprum29
|
67 |
14K |
1 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
67
|
14K
|
1
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Cuprum29
|
1.2K |
315K |
2 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
1.2K
|
315K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
3
|
|
ASX - By Stock
|
NOV |
Re:
Novatti - The $1 party
|
|
Cuprum29
|
4.6K |
1.3M |
0 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
4.6K
|
1.3M
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
1 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
168
|
47K
|
1
|
|
ASX - By Stock
|
NOV |
Re:
Novatti - The $1 party
|
|
Cuprum29
|
4.6K |
1.3M |
2 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
4.6K
|
1.3M
|
2
|
|
ASX - By Stock
|
TRP |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Cuprum29
|
47 |
8.1K |
2 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
47
|
8.1K
|
2
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL to Present at Bioshares Biotech Summit - Presentation
|
|
Cuprum29
|
67 |
14K |
3 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
67
|
14K
|
3
|
|
ASX - By Stock
|
TRP |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Cuprum29
|
47 |
8.1K |
3 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
47
|
8.1K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
5 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
168
|
47K
|
5
|
|
ASX - By Stock
|
FFG |
Re:
General Thoughts
|
|
Cuprum29
|
34 |
17K |
2 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
34
|
17K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
|
|
Cuprum29
|
238 |
66K |
3 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
238
|
66K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
5 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
168
|
47K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
6 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
168
|
47K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
7 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
168
|
47K
|
7
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Cuprum29
|
168 |
47K |
7 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
168
|
47K
|
7
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
2 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
75
|
23K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
1 |
17/07/24 |
17/07/24 |
ASX - By Stock
|
75
|
23K
|
1
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Quarterly Activity Report & Appendix 4C
|
|
Cuprum29
|
27 |
9.1K |
19 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
27
|
9.1K
|
19
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
1 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
75
|
23K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
5 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
75
|
23K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
3 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
75
|
23K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
2 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
75
|
23K
|
2
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron Travelan record sales globally, Australia and USA
|
|
Cuprum29
|
23 |
6.6K |
0 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
23
|
6.6K
|
0
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Trading Halt
|
|
Cuprum29
|
75 |
23K |
2 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
75
|
23K
|
2
|
|
ASX - By Stock
|
TRP |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Cuprum29
|
47 |
8.1K |
1 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
47
|
8.1K
|
1
|
|
ASX - By Stock
|
NOV |
Re:
Novatti - The $1 party
|
|
Cuprum29
|
4.6K |
1.3M |
4 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
4.6K
|
1.3M
|
4
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Cuprum29
|
1.2K |
315K |
4 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
1.2K
|
315K
|
4
|
|
ASX - By Stock
|
PER |
Re:
per-chart
|
|
Cuprum29
|
1.2K |
315K |
7 |
13/07/24 |
13/07/24 |
ASX - By Stock
|
1.2K
|
315K
|
7
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Immuron CEO Steven Lydeamore presentation to Sharewise
|
|
Cuprum29
|
24 |
5.5K |
2 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
24
|
5.5K
|
2
|
|
ASX - By Stock
|
NOV |
Re:
Novatti - The $1 party
|
|
Cuprum29
|
4.6K |
1.3M |
3 |
12/07/24 |
12/07/24 |
ASX - By Stock
|
4.6K
|
1.3M
|
3
|
|
ASX - By Stock
|
NOV |
Re:
Novatti - The $1 party
|
|
Cuprum29
|
4.6K |
1.3M |
2 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
4.6K
|
1.3M
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Cuprum29
|
832 |
332K |
6 |
10/07/24 |
10/07/24 |
ASX - By Stock
|
832
|
332K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Cuprum29
|
832 |
332K |
2 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
832
|
332K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Cuprum29
|
832 |
332K |
3 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
832
|
332K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
Cuprum29
|
832 |
332K |
4 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
832
|
332K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Record Quarterly and Yearly Revenue Show Outstanding Growth
|
|
Cuprum29
|
34 |
8.1K |
11 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
34
|
8.1K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Resubmits BLA with FDA for Ryoncil Approval
|
|
Cuprum29
|
265 |
105K |
2 |
09/07/24 |
09/07/24 |
ASX - By Stock
|
265
|
105K
|
2
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Travelan to progress to Phase 3 Clinical Trials in the US
|
|
Cuprum29
|
214 |
64K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
214
|
64K
|
1
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Travelan to progress to Phase 3 Clinical Trials in the US
|
|
Cuprum29
|
214 |
64K |
0 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
214
|
64K
|
0
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Travelan to progress to Phase 3 Clinical Trials in the US
|
|
Cuprum29
|
214 |
64K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
214
|
64K
|
1
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Travelan to progress to Phase 3 Clinical Trials in the US
|
|
Cuprum29
|
214 |
64K |
1 |
08/07/24 |
08/07/24 |
ASX - By Stock
|
214
|
64K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Notification regarding unquoted securities - PER
|
|
Cuprum29
|
87 |
20K |
3 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
87
|
20K
|
3
|
|
ASX - By Stock
|
NOV |
Re:
Ann: Pipeline of Over 500 New Merchants to be Onboarded
|
|
Cuprum29
|
13 |
6.3K |
4 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
13
|
6.3K
|
4
|
|
ASX - By Stock
|
IMC |
Re:
Ann: Travelan to progress to Phase 3 Clinical Trials in the US
|
|
Cuprum29
|
214 |
64K |
1 |
06/07/24 |
06/07/24 |
ASX - By Stock
|
214
|
64K
|
1
|
|